A 42-year-old woman with a history of severe asthma is brought to the emergency department in acute respiratory distress. She is wheezing bilaterally, SpO₂ is 82% on room air, and peak expiratory flow is severely reduced. She has received nebulized salbutamol (albuterol) twice in the past 2 hours without adequate response. Her blood pressure is 105/68 mmHg and heart rate is 118 bpm. Intravenous corticosteroids and magnesium sulfate have been initiated. The attending physician decides to administer a subcutaneous injection of an adrenergic agonist for acute bronchospasm relief. Which agent is most appropriate?

Explanation

## Clinical Context: Acute Severe Asthma (Status Asthmaticus) Refractory to β₂-Agonists This patient has: - Acute severe asthma unresponsive to repeated nebulized β₂-agonists (salbutamol) - Severe hypoxemia (SpO₂ 82%) - Severe airflow obstruction (reduced peak flow) - Tachycardia and tachypnea - Hemodynamically stable (BP 105/68) ## Why Adrenaline (Epinephrine) is Correct **Key Point:** Subcutaneous adrenaline is the gold standard for acute severe asthma refractory to inhaled β₂-agonists because it is the only agent that combines: 1. **Potent β₂-adrenergic effects** → bronchodilation (smooth muscle relaxation) 2. **α-adrenergic effects** → reduces airway mucosal edema and secretions 3. **Rapid onset** (within 5–15 minutes subcutaneously) **High-Yield:** Adrenaline is the ONLY catecholamine with significant β₂ activity suitable for subcutaneous administration in acute asthma. It is the recommended agent in international asthma guidelines (GINA, BTS) for life-threatening asthma. **Mnemonic: EPIPEN for Emergency** — **E**pinephrine, **P**otent β₂ + α, **I**mmediate action, **P**erfect for asthma, **E**mergency use, **N**o alternatives. ## Receptor Profile and Mechanism in Asthma | Agent | β₂ | α₁ | β₁ | Bronchodilation | Edema Reduction | Route | |-------|-----|-----|-----|-------|-------|-------| | **Adrenaline** | +++++ | +++ | ++ | **Excellent** | **Yes** | SC/IM | | Salbutamol (inhaled) | +++++ | — | — | Good (local) | No | Inhaled | | Noradrenaline | — | +++++ | ++ | **None** | No | IV only | | Phenylephrine | — | +++++ | — | **None** | Minimal | SC/IV | | Dobutamine | — | — | +++++ | **None** | No | IV only | **Clinical Pearl:** In acute asthma, the β₂-adrenergic effect is essential for bronchodilation. Agents lacking β₂ activity (noradrenaline, phenylephrine, dobutamine) will NOT relieve bronchospasm and may even worsen outcomes by increasing airway resistance through unopposed α-effects. ## Dosing and Administration **Adrenaline for acute asthma:** - **Dose:** 0.3–0.5 mg (0.3–0.5 mL of 1:1000 solution) subcutaneously - **Onset:** 5–15 minutes - **Repeat:** May repeat every 15–20 minutes if needed (up to 3 doses) - **Alternative route:** 0.1–0.2 mg (0.1–0.2 mL of 1:1000 solution) IM if IV access available **Key Point:** IM adrenaline is preferred over SC in modern practice (faster, more reliable absorption), but both are acceptable. ## Why Other Options Fail 1. **Noradrenaline** — Lacks β₂ activity; causes vasoconstriction only; will NOT relieve bronchospasm; IV-only (not suitable for SC injection). 2. **Phenylephrine** — Pure α₁ agonist; no β₂ activity; will NOT bronchodilate; may worsen airway obstruction through unopposed α-effects. 3. **Dobutamine** — Primarily β₁ agonist; no β₂ activity; will NOT relieve bronchospasm; IV-only; inappropriate for acute asthma. ## Differential: When NOT to Use Adrenaline **Warning:** Adrenaline is contraindicated or requires caution in: - Coronary artery disease (risk of myocardial ischemia) - Uncontrolled hypertension - Hyperthyroidism - Pheochromocytoma However, in life-threatening asthma, the benefit of adrenaline far outweighs these risks.